Women planning families while managing chronic autoimmune conditions face critical decisions about pregnancy timing and monitoring. This reality becomes particularly complex for those with systemic sclerosis, where the interplay between immune dysfunction and pregnancy physiology remains poorly understood. The French GR2 prospective study tracked 58 pregnancies in women with confirmed or early-stage systemic sclerosis over six years, revealing a 26.4% rate of composite adverse outcomes among pregnancies continuing beyond 22 weeks. These complications included preterm births before 34 weeks, placental insufficiency, growth restriction, and fetal deaths. Despite these challenges, 91.4% of pregnancies resulted in live births, suggesting that while risks exist, successful outcomes remain achievable with appropriate monitoring. The study compared outcomes against France's general population data from the 2016 perinatal survey, providing crucial benchmarking for risk assessment. This research addresses a significant knowledge gap in reproductive medicine, as prospective pregnancy data for systemic sclerosis patients has been remarkably limited. The condition affects connective tissue throughout the body, potentially impacting placental development and maternal cardiovascular adaptation to pregnancy. The 26% adverse outcome rate, while concerning, establishes an evidence-based foundation for counseling women with systemic sclerosis about pregnancy risks. However, the study's relatively small cohort of 58 pregnancies limits statistical power for identifying specific predictive factors. Additionally, the French healthcare system's robust prenatal monitoring may not reflect outcomes in other healthcare contexts. This work represents incremental but important progress in understanding autoimmune disease-pregnancy interactions, though larger international collaborations will be needed to develop comprehensive risk stratification tools.